Akebia Therapeutics, Inc. (AKBA)
0.9747
-0.01
(-0.87%)
USD |
NASDAQ |
Sep 04, 16:00
0.9775
0.00 (0.00%)
After-Hours: 20:00
Akebia Therapeutics SG&A Expense (TTM) : 117.15M for June 30, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 117.15M |
| March 31, 2026 | 115.58M |
| December 31, 2025 | 110.88M |
| September 30, 2025 | 112.54M |
| June 30, 2025 | 109.83M |
| March 31, 2025 | 110.06M |
| December 31, 2024 | 109.76M |
| September 30, 2024 | 107.40M |
| June 30, 2024 | 103.69M |
| March 31, 2024 | 104.00M |
| December 31, 2023 | 103.47M |
| September 30, 2023 | 108.58M |
| June 30, 2023 | 117.64M |
| March 31, 2023 | 122.78M |
| December 31, 2022 | 142.18M |
| September 30, 2022 | 156.61M |
| June 30, 2022 | 171.21M |
| March 31, 2022 | 180.62M |
| December 31, 2021 | 177.63M |
| September 30, 2021 | 173.08M |
| June 30, 2021 | 166.74M |
| March 31, 2021 | 160.72M |
| December 31, 2020 | 157.36M |
| September 30, 2020 | 161.95M |
| June 30, 2020 | 156.18M |
| Date | Value |
|---|---|
| March 31, 2020 | 156.62M |
| December 31, 2019 | 152.98M |
| September 30, 2019 | 162.28M |
| June 30, 2019 | 137.56M |
| March 31, 2019 | 113.13M |
| December 31, 2018 | 87.13M |
| September 30, 2018 | 39.51M |
| June 30, 2018 | 35.88M |
| March 31, 2018 | 30.24M |
| December 31, 2017 | 27.01M |
| September 30, 2017 | 25.58M |
| June 30, 2017 | 23.78M |
| March 31, 2017 | 22.19M |
| December 31, 2016 | 22.21M |
| September 30, 2016 | 23.58M |
| June 30, 2016 | 22.52M |
| March 31, 2016 | 20.92M |
| December 31, 2015 | 18.50M |
| September 30, 2015 | 14.52M |
| June 30, 2015 | 13.57M |
| March 31, 2015 | 12.18M |
| December 31, 2014 | 12.54M |
| September 30, 2014 | 12.01M |
| June 30, 2014 | 9.871M |
| March 31, 2014 | 8.224M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Emergent BioSolutions, Inc. | 181.20M |
| Exelixis, Inc. | 533.92M |
| ADMA Biologics, Inc. | 103.25M |
| Arcutis Biotherapeutics, Inc. | 297.60M |
| Relay Therapeutics, Inc. | 50.06M |